Both regimens yielded high virologic response rates at 48 weeks; the tenofovir alafenamide regimen continued to show fewer effects on renal function and bone mineral density.
Among HIV-infected patients receiving antiretroviral therapy in an ACTG clinical trial, the risk of attempted or completed suicide was 2.5-fold higher among those assigned to efavirenz-containing regimens.
High levels of efficacy maintained with little additional toxicity or resistance with the elvitegravir regimen between Weeks 96 and 144
Higher rate of virologic suppression < 50 copies/mL at Week 48 with dolutegravir (90% vs 83%; P = .025) was largely driven by fewer withdrawals due to AEs or other reasons in the dolutegravir arm
Single-tablet integrase inhibitor regimen showed durable efficacy and safety vs currently preferred regimens.
Virologic failure at Week 48 was infrequent in previously untreated patients receiving lopinavir/ritonavir with either 1 or 2 NRTIs and was not associated with the emergence of PI resistance.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.